Tarsus Pharmaceuticals Completes Alkeus Acquisition to Bolster Retinal Pipeline

Key Facts

1Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals, a retinal disease-focused biotech company.

2The deal adds gildeuretinol (ALK-001), a Phase 3 investigational medicine for Stargardt's disease, to Tarsus' pipeline.

In a move reflecting its strategy to lead the eye care sector, Tarsus Pharmaceuticals has finalized the acquisition of Alkeus Pharmaceuticals, a biotech firm focused on retinal diseases. The transaction integrates gildeuretinol (ALK-001) into Tarsus' pipeline, a Phase 3 investigational medicine designed to treat Stargardt's disease. According to reports, the completion of this deal follows the satisfaction of customary closing conditions initially set forth in August 2026.

The acquisition adds a late-stage clinical asset to Tarsus' portfolio at a time when biotech firms are prioritizing high-potential therapies for unmet medical needs. Gildeuretinol targets the underlying biology of Stargardt's disease, which currently has no FDA-approved treatments, potentially positioning Tarsus as a first-in-class provider in this niche. This expansion relies on the ongoing global Phase 3 trials to validate the drug's efficacy and safety profile.

Market data for Tarsus' share price was unavailable at the close of September 4, 2026. Looking ahead, investors will be watching for clinical milestones related to the newly acquired pipeline and broader macroeconomic catalysts, such as the upcoming speech by Federal Reserve Chair Kevin Warsh, which may influence sentiment across the high-growth biotechnology sector.